EP1827466A2 - Zusammensetzung und verfahren zur erleichterung der heilung von nicht heilenden und langsam heilenden wunden und geschwüren - Google Patents
Zusammensetzung und verfahren zur erleichterung der heilung von nicht heilenden und langsam heilenden wunden und geschwürenInfo
- Publication number
- EP1827466A2 EP1827466A2 EP05826664A EP05826664A EP1827466A2 EP 1827466 A2 EP1827466 A2 EP 1827466A2 EP 05826664 A EP05826664 A EP 05826664A EP 05826664 A EP05826664 A EP 05826664A EP 1827466 A2 EP1827466 A2 EP 1827466A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- healing
- curcumin
- arginine
- composition
- nitroglycerin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010052428 Wound Diseases 0.000 title claims abstract description 71
- 208000027418 Wounds and injury Diseases 0.000 title claims abstract description 71
- 239000000203 mixture Substances 0.000 title claims abstract description 50
- 208000025865 Ulcer Diseases 0.000 title claims abstract description 41
- 230000036269 ulceration Effects 0.000 title claims abstract description 24
- 230000035876 healing Effects 0.000 title abstract description 40
- 238000000034 method Methods 0.000 title description 16
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 108
- 235000012754 curcumin Nutrition 0.000 claims abstract description 55
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims abstract description 55
- 229940109262 curcumin Drugs 0.000 claims abstract description 54
- 239000004148 curcumin Substances 0.000 claims abstract description 54
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims abstract description 37
- 238000011282 treatment Methods 0.000 claims abstract description 36
- 239000004475 Arginine Substances 0.000 claims abstract description 34
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 34
- 229960003711 glyceryl trinitrate Drugs 0.000 claims abstract description 32
- 239000000006 Nitroglycerin Substances 0.000 claims abstract description 24
- 239000006071 cream Substances 0.000 claims abstract description 10
- 239000003974 emollient agent Substances 0.000 claims abstract description 10
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims abstract description 8
- 239000002480 mineral oil Substances 0.000 claims abstract description 4
- 235000010446 mineral oil Nutrition 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 12
- 230000000699 topical effect Effects 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 5
- 239000004615 ingredient Substances 0.000 claims description 5
- 229940072991 nitro-bid Drugs 0.000 claims description 5
- 239000002674 ointment Substances 0.000 claims description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- 239000011701 zinc Substances 0.000 claims description 4
- 229910052725 zinc Inorganic materials 0.000 claims description 4
- 235000002961 Aloe barbadensis Nutrition 0.000 claims description 3
- 235000011399 aloe vera Nutrition 0.000 claims description 3
- 239000003921 oil Substances 0.000 claims description 3
- 244000186892 Aloe vera Species 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 abstract description 5
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 abstract description 4
- 229960003121 arginine Drugs 0.000 abstract description 2
- 239000011787 zinc oxide Substances 0.000 abstract description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 62
- 235000009697 arginine Nutrition 0.000 description 25
- 206010012601 diabetes mellitus Diseases 0.000 description 22
- 231100000397 ulcer Toxicity 0.000 description 16
- 230000029663 wound healing Effects 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- 230000004087 circulation Effects 0.000 description 11
- 230000003902 lesion Effects 0.000 description 10
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 9
- 229930064664 L-arginine Natural products 0.000 description 9
- 235000014852 L-arginine Nutrition 0.000 description 9
- 230000001010 compromised effect Effects 0.000 description 8
- 238000001804 debridement Methods 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 238000002266 amputation Methods 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- 230000033115 angiogenesis Effects 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 208000003790 Foot Ulcer Diseases 0.000 description 5
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000008929 regeneration Effects 0.000 description 5
- 238000011069 regeneration method Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000037314 wound repair Effects 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000024883 vasodilation Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010040943 Skin Ulcer Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000006471 dimerization reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000004088 microvessel Anatomy 0.000 description 3
- 230000000505 pernicious effect Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000001131 transforming effect Effects 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- MXCVHSXCXPHOLP-UHFFFAOYSA-N 4-oxo-6-propylchromene-2-carboxylic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=CC(CCC)=CC=C21 MXCVHSXCXPHOLP-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000008960 Diabetic foot Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000001217 buttock Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 229940124645 emergency medicine Drugs 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 150000002823 nitrates Chemical class 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000005067 remediation Methods 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 231100000019 skin ulcer Toxicity 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000010388 wound contraction Effects 0.000 description 2
- ZIUSSTSXXLLKKK-KOBPDPAPSA-N (1e,4z,6e)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one Chemical compound C1=C(O)C(OC)=CC(\C=C\C(\O)=C\C(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 ZIUSSTSXXLLKKK-KOBPDPAPSA-N 0.000 description 1
- CVHXQHIJOULCNQ-UHFFFAOYSA-N 1,3-dinitrooxypropan-2-yl nitrate;1-nitropropane-1,2,3-triol Chemical compound OCC(O)C(O)[N+]([O-])=O.[O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O CVHXQHIJOULCNQ-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N 2-Amino-2-Deoxy-Hexose Chemical compound NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- GVYBVPCYMLCVKB-INZIHYEWSA-N COC1=CC(=CC=C1O)C=CC(=O)CC(=O)C=CC1=CC=C(O)C(OC)=C1.N[C@@H](CCCNC(N)=N)C(=O)O.C(C(CO[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-] Chemical compound COC1=CC(=CC=C1O)C=CC(=O)CC(=O)C=CC1=CC=C(O)C(OC)=C1.N[C@@H](CCCNC(N)=N)C(=O)O.C(C(CO[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-] GVYBVPCYMLCVKB-INZIHYEWSA-N 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 206010021519 Impaired healing Diseases 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 102000008052 Nitric Oxide Synthase Type III Human genes 0.000 description 1
- 108010075520 Nitric Oxide Synthase Type III Proteins 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003217 anti-cancerogenic effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000005911 anti-cytotoxic effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- JYTVKRNTTALBBZ-UHFFFAOYSA-N bis demethoxycurcumin Natural products C1=CC(O)=CC=C1C=CC(=O)CC(=O)C=CC1=CC=CC(O)=C1 JYTVKRNTTALBBZ-UHFFFAOYSA-N 0.000 description 1
- PREBVFJICNPEKM-YDWXAUTNSA-N bisdemethoxycurcumin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)CC(=O)\C=C\C1=CC=C(O)C=C1 PREBVFJICNPEKM-YDWXAUTNSA-N 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- YXAKCQIIROBKOP-UHFFFAOYSA-N di-p-hydroxycinnamoylmethane Natural products C=1C=C(O)C=CC=1C=CC(=O)C=C(O)C=CC1=CC=C(O)C=C1 YXAKCQIIROBKOP-UHFFFAOYSA-N 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229940059904 light mineral oil Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 210000003049 pelvic bone Anatomy 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 231100000208 phytotoxic Toxicity 0.000 description 1
- 230000000885 phytotoxic effect Effects 0.000 description 1
- 235000003784 poor nutrition Nutrition 0.000 description 1
- 238000009101 premedication Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000035752 proliferative phase Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Definitions
- the present invention generally relates to an
- the present invention relates to an
- Wound healing is a highly complex process, involving
- Endothelial nitric oxide synthase eNOS/iNOS
- a healthy blood supply (local and systemic);
- Type II diabetes is one such factor, and is the most
- the CDC estimates the diabetes, both diagnosed
- Diabetes is a prevalent disease and an ever-growing
- Diabetes is reportedly
- diabetics have a fifteen percent
- diabetic foot ulcers will heal within six months-
- compositions or methods of treatment either alone or in
- composition and use thereof .obviates the need for
- the present invention provides a composition
- composition of the present invention comprises,
- aloe vera constituents are instrumental in maintaining
- composition was applied twice daily. After a total of
- Patient F had lost one finger tip to an ulcer and poor
- Patient F has an open scalp lesion of approximately
- Patient G had a developing lesion between her
- composition comprises: nitroglycerin (Nitrobid) 2%
- Curcumin Powder 95% (or a curcumin-containing ingredient,
- composition is formed as the triturate powders and wet
- the treatment protocol essentially involves leaving
- the wound is typically
- the present method increases blood flow to
- Nitroglycerin is a nitrate that has been approved by
- Nitroglycerin is a nitric oxide (NO) donor.
- NO is a nitric oxide (NO) donor.
- Nitroglycerin acts by donating nitric oxide, which
- microvessels microvessels .
- Non healing wounds especially in diabetic and
- Curcumin (diferuloylmethane) , is a natural product
- Curcuma longa (tumeric) plant Curcuma longa (tumeric) . Curcumin promotes wound
- Curcumin significantly accelerates wound healing as
- Curcumin increases eNos/iNOS within a wound.
- NO is a vital factor in wound healing
- iNOS inducible nitric oxide synthetase
- eNOS endothelial NO
- iNOS induced in large
- Curcumin enhances macrophage production (white
- Curcumin demonstrates anti-inflammatory action
- curcutninoids in tumeric demethoxy- or
- Curcumin helps fight off pathogens acting as a
- Neisseria gonorrhoeae-induced NF-kappaB signaling Neisseria gonorrhoeae-induced NF-kappaB signaling.
- Curcumin has antimicrobial action (Journal of
- Curcumin has antifungal properties - 100% phytotoxic
- Curcumin is anti-inflammatory, antioxidant,
- Curcumin shows antibacterial, anti-inflammatory, and antineoplastic activity (J Pharmacologic Pharmacology
- Curcumin enhances angiogenesis (Journal of
- Angiogenesis is a prerequisiste for wound healing.
- Curcumin is frequently studied for it's role in enhancing
- Curcumin has been shown in many animal studies to
- Topical curcumin enhances cutaneous wound healing in
- curcumin has been used in
- dimerization occurs rapidly, on a timescale of minutes.
- the dimmer is stable (Journal of Biological
- Arginine is a substrate to make NO, a particular
- amino acid L-arginine is the only substrate for nitric oxide
- NO is a small radical, formed directly from the
- Curcumin by inflammatory cells, mainly macrophages. Curcumin
- the wound site (or any other tissue site of
- nitroglycerine "opens the door"
- the primary active ingredients are Nitroglycerin, Arginine, and
- Nitroglycerin is in the form of two percent ointment
- compositions of the present invention may be prepared
- composition for remediation of dermal anomalies Composition for remediation of dermal anomalies
- the formed composition may then be applied topically
- Curcumin is presently shown at an.08%
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/992,623 US7731993B2 (en) | 2004-11-17 | 2004-11-17 | Composition for treating a dermal anomaly |
| US10/992,636 US20060105027A1 (en) | 2004-11-17 | 2004-11-17 | Method for treating skin ulcers |
| PCT/US2005/041708 WO2006055726A2 (en) | 2004-11-17 | 2005-11-17 | Composition and method for facilitating the healing of non-healing and slow-healing wounds and ulcerations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP1827466A2 true EP1827466A2 (de) | 2007-09-05 |
| EP1827466A4 EP1827466A4 (de) | 2009-11-11 |
Family
ID=36407755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP05826664A Withdrawn EP1827466A4 (de) | 2004-11-17 | 2005-11-17 | Zusammensetzung und verfahren zur erleichterung der heilung von nicht heilenden und langsam heilenden wunden und geschwüren |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1827466A4 (de) |
| JP (1) | JP2008520694A (de) |
| AU (1) | AU2005307736A1 (de) |
| BR (1) | BRPI0517731A (de) |
| CA (1) | CA2588119A1 (de) |
| IL (1) | IL183117A0 (de) |
| WO (1) | WO2006055726A2 (de) |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0665647B2 (ja) * | 1985-06-12 | 1994-08-24 | 株式会社三和化学研究所 | 移植皮膚処置剤 |
| US5196185A (en) * | 1989-09-11 | 1993-03-23 | Micro-Collagen Pharmaceutics, Ltd. | Collagen-based wound dressing and method for applying same |
| US5698589A (en) * | 1993-06-01 | 1997-12-16 | International Medical Innovations, Inc. | Water-based topical cream containing nitroglycerin and method of preparation and use thereof |
| US5401504B1 (en) * | 1993-12-28 | 1998-04-21 | Univ Mississippi Medical Cente | Use of tumeric in wound healing |
| US5925376C1 (en) * | 1994-01-10 | 2001-03-20 | Madalene C Y Heng | Method for treating psoriasis using selected phosphorylase kinase inhibitor and additional compounds |
| AU2282395A (en) * | 1994-05-27 | 1995-12-21 | Neptune Pharmaceutical Corporation | Nitric oxide donor composition and method for treatment of anal disorders |
| US5543430A (en) * | 1994-10-05 | 1996-08-06 | Kaesemeyer; W. H. | Method and formulation of stimulating nitric oxide synthesis |
| US5891472A (en) * | 1996-11-19 | 1999-04-06 | Meri Charmyne Russell | Treatment of equine laminitis |
| JP3667027B2 (ja) * | 1997-03-06 | 2005-07-06 | 株式会社ノエビア | 皮膚外用剤 |
| CN1298309A (zh) * | 1998-02-27 | 2001-06-06 | 同步神经元有限责任公司 | 治疗肛门区疼痛的方法及其组合物 |
| US6627632B2 (en) * | 1998-12-14 | 2003-09-30 | Cellegy Pharmaceuticals, Inc. | Compositions and methods for the treatment of anorectal disorders |
| US20030104033A1 (en) * | 2001-07-13 | 2003-06-05 | Lai Chon-Si | Enteral formulations |
| US20030091601A1 (en) * | 2001-11-13 | 2003-05-15 | Abat Inc. | Use of topical arginine to enhance wound healing |
-
2005
- 2005-11-17 CA CA002588119A patent/CA2588119A1/en not_active Abandoned
- 2005-11-17 AU AU2005307736A patent/AU2005307736A1/en not_active Abandoned
- 2005-11-17 WO PCT/US2005/041708 patent/WO2006055726A2/en active Application Filing
- 2005-11-17 JP JP2007543244A patent/JP2008520694A/ja active Pending
- 2005-11-17 BR BRPI0517731-6A patent/BRPI0517731A/pt not_active IP Right Cessation
- 2005-11-17 EP EP05826664A patent/EP1827466A4/de not_active Withdrawn
-
2007
- 2007-05-10 IL IL183117A patent/IL183117A0/en unknown
Non-Patent Citations (10)
| Title |
|---|
| ALI IBN ABBAS MAJOOSI: "Dawa-e-Afs", KEY ATTRIBUTES OF TKDL AH3/1631, pages 1 - 2, XP003025233 |
| ALI IBN ABBAS MAJOOSI: "Zaroor-e-Sibr", KEY ATTRIBUTES OF TKDL AH3/1627, pages 1 - 2, XP003025232 |
| AMINUDDAULA: "Marham-e-Khall", KEY ATTRIBUTES OF TKDL MA2/678A, pages 1 - 2, XP003025230 |
| KALI DASA: "Lakucadi Yoga", KEY ATTRIBUTES OF TKDL RS14/438, pages 1 - 2, XP003025228 |
| MOHD AZAM KHAN: "Zimaad-e-Aahak", KEY ATTRIBUTES OF TKDL MH3/49L, pages 1 - 2, XP003025226 |
| MOHD AZAM KHAN: "Zimaad-e-Mudammil", KEY ATTRIBUTES OF TKDL AA26/115C, pages 1 - 2, XP003025229 |
| MOHD NAJMUL GHANI KHAN: "Zaroor Bara-e-Qurooh", KEY ATTRIBUTES OF TKDL JA6/1040D, pages 1 - 2, XP003025224 |
| MOHD SHAREEF KHAN: "Marham-e-Khall/Jaalinos Bara-e-Qurooh-b", KEY ATTRIBUTES OF TKDL MH1/4111B, pages 1 - 3, XP003025231 |
| SUSRUTA: "Vranacikitsa - 02", KEY ATTRIBUTES OF TKDL AT/743, pages 1 - 2, XP003025225 |
| VANGASENA: "Sarsapadi Lepa", KEY ATTRIBUTES OF TKDL AK11/2350, pages 1 - 2, XP003025227 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006055726A3 (en) | 2007-03-22 |
| CA2588119A1 (en) | 2006-05-26 |
| WO2006055726A2 (en) | 2006-05-26 |
| IL183117A0 (en) | 2007-10-31 |
| BRPI0517731A (pt) | 2008-10-21 |
| JP2008520694A (ja) | 2008-06-19 |
| AU2005307736A1 (en) | 2006-05-26 |
| EP1827466A4 (de) | 2009-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3773764B1 (de) | Zusammensetzung zur behandlung von chronischen wunden | |
| JP6495183B2 (ja) | 表面の創傷を処置するための組成物および方法 | |
| AU2010257466B2 (en) | Epidermal growth factor composition, a process therefor and its application | |
| AU2002312416A1 (en) | Compositions and methods for the prophylaxis and treatment of aphthous ulcers and herpes simplex lesions | |
| US8492435B2 (en) | Composition for treating a dermal anomaly | |
| JPH09510978A (ja) | 皮膚と髪のための殿粉−金属錯体 | |
| SK287249B6 (sk) | Liečivé produkty s cikatrizačným účinkom obsahujúce biguanidové deriváty | |
| WO2008104076A1 (en) | Electrocolloidal silver and echinacea root antimicrobial formulation | |
| KR101451816B1 (ko) | 당뇨병성 창상의 예방 또는 치료용 약학 조성물 | |
| WO1994005272A1 (en) | Skin treatment compositions containing dimethylsulphone and dimethylsulphoxide | |
| WO1994005293A1 (en) | Skin treatment compositions containing dimethylsulphone and allopurinol or oxypurinol | |
| WO2006055726A2 (en) | Composition and method for facilitating the healing of non-healing and slow-healing wounds and ulcerations | |
| WO1994005279A1 (en) | Dermatological treatment compositions containing dimethylsulphone and a sulfur containing amino acid | |
| US20080045604A1 (en) | Composition and method for facilitating the healing of non-healing and slow-healing wounds and ulcerations | |
| EP1397124B1 (de) | Verwendung von antidiabetika zur herstellung eines vernarbungsfördernden arzneimittels | |
| Rajashri et al. | Curcuma Longa and Pineapple Extract Paste in the management of Alveolar Osteitis: An Experimental study | |
| US20220249543A1 (en) | Trona Based Therapeutic Compositions and Use and Manufacture Thereof | |
| US20060105027A1 (en) | Method for treating skin ulcers | |
| US20100189668A1 (en) | Composition for treating herpes simplex viral infections, the method, use and process by which the composition is utilized and the manufacture of the composition | |
| LV13450B (en) | Novel medicinal use of meldonium and pharmaceutical compositions thereof | |
| WO2015159206A1 (en) | Copper alloy microparticles for use in the treatment of an external skin lesion | |
| KR20140104932A (ko) | 당뇨병성 창상의 예방 또는 치료용 약학 조성물 | |
| JPH07118165A (ja) | カルシトニン遺伝子関連ペプチド類を含有する経皮吸収組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20070613 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
| AX | Request for extension of the european patent |
Extension state: AL BA HR MK YU |
|
| DAX | Request for extension of the european patent (deleted) | ||
| TPAC | Observations filed by third parties |
Free format text: ORIGINAL CODE: EPIDOSNTIPA |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20090907 |
|
| 17Q | First examination report despatched |
Effective date: 20100222 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20120601 |